average weekly weight loss tirzepatide New drug delivers significant and long-lasting Depicts the mean percentage of

Patient safety guidance should include: Education about expected appetite changes and strategies for maintaining adequate nutrition Monitoring for excessive weight loss or signs of malnutrition Assessment of mental health at follow-up visits Clear instructions to report severe or persistent nausea, vomiting, or neuropsychiatric symptoms Awareness that cognitive effects remain investigational and should not influence prescribing decisions Reporting severe persistent abdominal pain (pancreatitis), right upper quadrant pain/jaundice (gallbladder disease), severe abdominal distension with inability to pass gas or stool (possible ileus), persistent vomiting or signs of dehydration, and new/worsening vision changes (retinopathy) Understanding increased hypoglycemia risk when combined with insulin or sulfonylureas GLP-1 receptor agonists are contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and should be used with caution in patients with severe gastrointestinal disease, including gastroparesis

Scott Butsch, director de medicina para la obesidad en la Clnica Cleveland

Your provider can use biomarker and genetic data to guide selection of the approach most likely to support your long-term metabolic health

Dietary strategies form the foundation of side effect management

Keep them in the original container with the lid tightly sealed

Do not discontinue the medication without consulting your healthcare provider, even if you feel better